全文获取类型
收费全文 | 178篇 |
免费 | 35篇 |
国内免费 | 27篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 3篇 |
基础医学 | 24篇 |
临床医学 | 18篇 |
内科学 | 104篇 |
皮肤病学 | 2篇 |
外科学 | 10篇 |
综合类 | 16篇 |
预防医学 | 11篇 |
药学 | 48篇 |
中国医学 | 2篇 |
肿瘤学 | 1篇 |
出版年
2023年 | 8篇 |
2022年 | 24篇 |
2021年 | 33篇 |
2020年 | 21篇 |
2019年 | 15篇 |
2018年 | 20篇 |
2017年 | 12篇 |
2016年 | 18篇 |
2015年 | 18篇 |
2014年 | 15篇 |
2013年 | 17篇 |
2012年 | 8篇 |
2011年 | 8篇 |
2010年 | 5篇 |
2009年 | 3篇 |
2008年 | 5篇 |
2007年 | 5篇 |
2006年 | 2篇 |
2005年 | 1篇 |
2003年 | 1篇 |
2002年 | 1篇 |
排序方式: 共有240条查询结果,搜索用时 46 毫秒
1.
2.
目的 评估替诺福韦(tenofovir,TDF)作为一线治疗方案的HIV/AIDS患者慢性肾病(chronic kidney disease,CKD)发生情况及其影响因素。方法 采用回顾性队列研究方法,收集分析TDF组和齐多夫定(zidovudine,AZT)组HIV/AIDS的人口学信息及临床检查资料,比较2组患者CKD的发生率和差异,多因素Cox比例风险模型分析TDF组患者CKD发生的影响因素。结果 共纳入432例HIV/AIDS患者,其中TDF组249例,AZT组193例,开始治疗时年龄中位数分别为32(26,50)、31(26,43)岁,传播途径主要以同性传播为主(分别为69.48%、82.90%)。TDF组与AZT组24个月CKD累积发生率分别是2.8%和0,差异有统计学意义(P<0.05)。各时间点肾小球滤过率(eGFR)值中,AZT组均高于TDF组(均P<0.01)。多因素Cox比例风险模型分析显示:TDF组患者中,女性(HR=57.46,95% CI:2.981~67.684)和基线eGFR异常(HR=4.75,95% CI:1.351~16.702)者发生CKD的风险更高。结论 TDF可以引起HIV/AIDS患者CKD的发生,但发生率较低,女性和基线eGFR异常者发生CKD的风险更高。在临床治疗过程中,要密切关注女性患者以及评估患者肾功能。 相似文献
3.
4.
5.
《Health Policy and Technology》2014,3(1):59-65
ObjectivesCountry decision-making regarding adoption of new health technologies is a lengthy process that is informed by scientific, public health, and policy analyses. Key Opinion Leaders (KOLs), who include a range of influential individuals (e.g., Ministry of Health officials, leaders of medical and pharmacy associations, civil society representatives, donors), play a critical role in country decision-making around adoption and availability of new HIV-prevention tools. Their perspectives can shape public opinion and influence policy, programming, and procurement decisions.MethodsIn-depth face-to-face interviews with a dozen purposefully selected national KOLs in India were conducted to gain their perspectives around ARV-based prevention for women, focusing on microbicides in general and tenofovir vaginal gel specifically. Theme-based content emerged and was analyzed using ATLAS.ti software.ResultsWhile generally supportive, KOLs expressed caveats regarding the role tenofovir gel might play in the overall HIV-prevention program. Key outstanding issues that would need to be addressed include product effectiveness, potential for resistance, product cost, feasibility of HIV testing and re-testing, and effective targeting of key populations for public health impact.ConclusionsAs new HIV-prevention technologies advance through clinical trials, there is a concomitant necessity to engage in policy analysis exercises. Formative research with stakeholders early in the process is an important yet often overlooked step. The potential role that the tenofovir gel could play in India will depend in large part on epidemiological, public health, and economic factors. Understanding target populations' perspectives on the product will also be critical for its successful introduction. 相似文献
6.
徐一铭 《中国实用乡村医生杂志》2021,(3):61-64
目的探讨替诺福韦酯在乙型病毒性肝炎合并肝硬化患者挽救治疗中的应用效果。方法收集2014-2017年沈阳市第六人民医院收治的乙肝合并肝硬化拉夫米定抗病毒治疗失败的患者89例,以替诺福韦酯进行挽救治疗%周。分别依据挽救治疗前患者HBV定量和谷丙转氨酶(ALT)水平将患者进行分组,比较不同分组情况下HBV累积应答率、乙型肝炎E抗原(HBeAg)累积转换率和ALT累积复常率。结果本组89例患者中,HBV累积应答64例,占71.91%;HBeAg累积转换32例,占35.96%;ALT累积复常74例,占83.15%。低定量组与高定量组HBV累积应答率、HBeAg累积转换率、ALT累积复常率差异均有统计学意义(P值均<0.05)。低转氨酶组与高转氨酶组HBV累积应答率、HBeAg累积转换率、ALT累积复常率差异均无统计学意义(P值均>0.05)。结论替诺福韦酯作为挽救治疗用药,可有效抑制乙型肝炎病毒复制,改善转氨酶和肝炎抗体指标,尤其是对病毒定量水平较低的患者,效果更为明显。 相似文献
7.
《Revista de gastroenterologia de Mexico》2021,86(4):403-432
Hepatitis B virus (HBV) infection continues to be a worldwide public health problem. In Mexico, at least three million adults are estimated to have acquired hepatitis B (total hepatitis B core antibody [anti-HBc]-positive), and of those, 300,000 active carriers (hepatitis B surface antigen [HBsAg]-positive) could require treatment. Because HBV is preventable through vaccination, its universal application should be emphasized. HBV infection is a major risk factor for developing hepatocellular carcinoma. Semi-annual liver ultrasound and serum alpha-fetoprotein testing favor early detection of that cancer and should be carried out in all patients with chronic HBV infection, regardless of the presence of advanced fibrosis or cirrhosis. Currently, nucleoside/nucleotide analogues that have a high barrier to resistance are the first-line therapies. 相似文献
8.
Sang Kyung Jung Kyung-Ah Kim So Young Ha Hyun Kyo Lee Young Doo Kim Bu Hyun Lee Woo Hyun Paik Jong Wook Kim Won Ki Bae Nam-Hoon Kim June Sung Lee Yoon Jung Jwa 《Clinical and molecular hepatology》2015,21(1):41-48
Background/Aims
This study investigated the antiviral effects of tenofovir disoproxil fumarate (TDF) monotherapy in nucleos(t)ide analogue (NA)-naive and NA-experienced chronic hepatitis B (CHB) patients.Methods
CHB patients treated with TDF monotherapy (300 mg/day) for ≥12 weeks between December 2012 and July 2014 at a single center were retrospectively enrolled. Clinical, biochemical, and virological parameters were assessed every 12 weeks.Results
In total, 136 patients (median age 49 years, 96 males, 94 HBeAg positive, and 51 with liver cirrhosis) were included. Sixty-two patients were nucleos(t)ide (NA)-naïve, and 74 patients had prior NA therapy (NA-exp group), and 31 patients in the NA-exp group had lamivudine (LAM)-resistance (LAM-R group). The baseline serum hepatitis B virus (HBV) DNA level was 4.9±2.3 log IU/mL (mean±SD), and was higher in the NA-naïve group than in the NA-exp and LAM-R groups (5.9±2.0 log IU/mL vs 3.9±2.0 log IU/mL vs 4.2±1.7 log IU/mL, P<0.01). The complete virological response (CVR) rate at week 48 in the NA-naïve group (71.4%) did not differ significantly from those in the NA-exp (71.3%) and LAM-R (66.1%) groups. In multivariate analysis, baseline serum HBV DNA was the only predictive factor for a CVR at week 48 (hazard ratio, 0.809; 95% confidence interval, 0.729-0.898), while the CVR rate did not differ with the NA experience.Conclusions
TDF monotherapy was effective for CHB treatment irrespective of prior NA treatment or LAM resistance. Baseline serum HBV DNA was the independent predictive factor for a CVR. 相似文献9.
目的探讨替诺福韦酯治疗HBeAg阳性慢性乙型肝炎患者的疗效及对肝功能指标的影响。方法选取2017年2月至2018年3月本院收治的126例HBeAg阳性慢性乙型肝炎患者,按照年龄、性别组间具有可比性原则分为对照组与观察组,各63例。对照组予以恩替卡韦治疗,观察组予以替诺福韦酯治疗,比较两组治疗前后肝功能指标及ALT复常率、HBV DNA转阴率、HBeAg转阴率。结果治疗后,两组AST、ALT、TBiI均低于治疗前,且观察组低于对照组,ALB高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);观察组ALT复常率、HBV DNA阴转率、HBeAg转阴率均高于对照组,差异有统计学意义(P<0.05)。结论相比恩替卡韦治疗,替诺福韦酯治疗HBeAg阳性慢性乙型肝炎患者,可有效改善肝功能,提高HBV DNA阴转率及HBeAg阴转率。 相似文献
10.
目的 比较替诺福韦与恩替卡韦再治疗对α-干扰素治疗不应答的慢性乙型肝炎(CHB)患者的疗效。方法 2016年6月~2020年3月我院诊治的CHB患者77例,均为接受过聚乙二醇α-干扰素治疗6个月后不应答的患者,其中接受替诺福韦治疗者41例,接受恩替卡韦治疗者36例。采用实时荧光定量PCR法检测血清HBV DNA载量,采用ELISA法检测血清HBsAg和HBeAg,使用CytoFLEX型流式细胞仪检测外周血CD4+和CD8+T淋巴细胞亚群。结果 在治疗6个月和12个月末,替诺福韦治疗组血清ALT复常率分别为80.5%和90.2%,与恩替卡韦治疗组的77.8%和86.1%比,差异均无统计学意义(P>0.05),血清HBV DNA转阴率分别为65.9%和95.1%,与恩替卡韦治疗组的63.9%和88.9%比,差异也无统计学意义(P>0.05);替诺福韦治疗组外周血CD4+细胞百分比分别为(33.9±3.9)%和(38.6±5.6)%,显著高于恩替卡韦治疗的【(30.2±3.7)%和(35.1±3.6)%,P<0.05】,CD4+/CD8+细胞比值分别为(1.2±0.1)和(1.5±0.1),显著高于恩替卡韦治疗组[(1.0±0.0)和(1.3±0.1),P<0.05];在12个月的观察期内,替诺福韦治疗组耐药发生率为4.9%,与恩替卡韦治疗组的2.8%比,差异无统计学意义(x2=0.013,P=0.908)。结论 替诺福韦与恩替卡韦治疗对聚乙二醇α-干扰素治疗不应答的CHB患者均可获得很好的疗效,但替诺福韦在提高免疫功能方面优于恩替卡韦治疗,延长疗程观察是否能提高血清HBeAg转阴率值得研究。 相似文献